Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a beta‑blocker (selective β1‑adrenergic antagonist) presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, helping to lower blood pressure by reducing heart rate and peripheral vascular resistance.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets, for reliable patient care and therapeutic continuity.

Nebivolol is a selective β1‑blocker used in cardiovascular disease management.

Hypertension: lowers systolic and diastolic blood pressure in adult patients. Heart failure (reduced ejection fraction): improves ventricular function and symptoms. Post‑myocardial infarction remodeling: may aid in reducing adverse cardiac remodeling.

Nebivolol may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion. - Bradycardia: slower than normal heart rate. - Gastrointestinal discomfort, such as nausea.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Acute heart failure decompensation. - Bronchospasm in patients with reactive airway disease. - Significant hypotension causing syncope. - Allergic reactions including rash or angioedema.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Cardiovascular assessment: evaluate heart rate, blood pressure, and cardiac function. - Respiratory disease: use cautiously in asthma or COPD. - Diabetes mellitus: monitor blood glucose as beta‑blockade may mask hypoglycaemia symptoms. - Concomitant medications: review for potential interactions that affect heart rate or blood pressure. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Combined use with other β‑blockers or calcium‑channel blockers that depress cardiac conduction. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine) that may increase nebivolol plasma levels. - Non‑selective β‑blockers in patients with severe asthma.

Moderate Interactions (Monitor Closely):\n- Antihypertensives such as ACE inhibitors or diuretics may enhance hypotensive effect. - Antidiabetic agents: beta‑blockade can mask hypoglycaemia signs. - Antidepressants (e.g., SSRIs) that have mild CYP2D6 inhibition.